Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

210 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Future directions and management of liquid biopsy in non-small cell lung cancer.
Cossu AM, Scrima M, Lombardi A, Grimaldi A, Russo M, Ottaiano A, Caraglia M, Bocchetti M. Cossu AM, et al. Among authors: ottaiano a. Explor Target Antitumor Ther. 2020;1(4):239-252. doi: 10.37349/etat.2020.00015. Epub 2020 Aug 31. Explor Target Antitumor Ther. 2020. PMID: 36046776 Free PMC article. Review.
The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronic acid is inversely correlated to skeletal related events (SRE).
Facchini G, Caraglia M, Santini D, Nasti G, Ottaiano A, Striano S, Maiolino P, Ruberto M, Fiore F, Tonini G, Budillon A, Iaffaioli RV, Zeppetella GL. Facchini G, et al. Among authors: ottaiano a. J Exp Clin Cancer Res. 2007 Sep;26(3):307-12. J Exp Clin Cancer Res. 2007. PMID: 17987788 Clinical Trial.
First Biologic Drug in the Treatment of RAS Wild-Type Metastatic Colorectal Cancer: Anti-EGFR or Bevacizumab? Results From a Meta-Analysis.
Ottaiano A, De Stefano A, Capozzi M, Nappi A, De Divitiis C, Romano C, Silvestro L, Cassata A, Casaretti R, Tafuto S, Caraglia M, Berretta M, Nasti G, Avallone A. Ottaiano A, et al. Front Pharmacol. 2018 May 3;9:441. doi: 10.3389/fphar.2018.00441. eCollection 2018. Front Pharmacol. 2018. PMID: 29773991 Free PMC article. Review.
Genetic trajectory and immune microenvironment of lung-specific oligometastatic colorectal cancer.
Ottaiano A, Circelli L, Lombardi A, Scala S, Martucci N, Galon J, Buonanno M, Scognamiglio G, Botti G, Hermitte F, Savarese G, D'Amore L, Tatangelo F, Di Mauro A, Liguori G, Trotta AM, Napolitano M, Capozzi M, Tafuto S, Perri F, La Rocca A, Caraglia M, Nasti G. Ottaiano A, et al. Cell Death Dis. 2020 Apr 24;11(4):275. doi: 10.1038/s41419-020-2480-6. Cell Death Dis. 2020. PMID: 32332709 Free PMC article.
Evolution of Mutational Landscape and Tumor Immune-Microenvironment in Liver Oligo-Metastatic Colorectal Cancer.
Ottaiano A, Caraglia M, Di Mauro A, Botti G, Lombardi A, Galon J, Luce A, D'Amore L, Perri F, Santorsola M, Hermitte F, Savarese G, Tatangelo F, Granata V, Izzo F, Belli A, Scala S, Delrio P, Circelli L, Nasti G. Ottaiano A, et al. Cancers (Basel). 2020 Oct 21;12(10):3073. doi: 10.3390/cancers12103073. Cancers (Basel). 2020. PMID: 33096795 Free PMC article.
Aflibercept or bevacizumab in combination with FOLFIRI as second-line treatment of mRAS metastatic colorectal cancer patients: the ARBITRATION study protocol.
Ottaiano A, Scala S, Santorsola M, Trotta AM, D'Alterio C, Portella L, Clemente O, Nappi A, Zanaletti N, De Stefano A, Avallone A, Granata V, Notariello C, Luce A, Lombardi A, Picone C, Petrillo A, Perri F, Tatangelo F, Di Mauro A, Albino V, Izzo F, Rega D, Pace U, Di Marzo M, Chiodini P, De Feo G, Del Prete P, Botti G, Delrio P, Caraglia M, Nasti G. Ottaiano A, et al. Ther Adv Med Oncol. 2021 Mar 24;13:1758835921989223. doi: 10.1177/1758835921989223. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 33854566 Free PMC article.
210 results